This industry article is from Pharma Conversations Podcast, hosted by Shada Warreth and Elizabeth Hunt.
This article was authored by Patrick Nieuwenhuizen, Managing Director Consultant at Paradigm Pharmaceutical Quality Consultancy. The views and opinions expressed are solely those of the author and do not necessarily reflect the positions of any affiliated organisations.
This episode was sponsored by Ecolab, whose support made production possible. Sponsorship does not influence the content, discussions, or viewpoints presented.
Unannounced inspections have become one of the most transformative developments in the pharmaceutical regulatory environment, reshaping how companies think about compliance, operational discipline, and quality culture. In a recent episode of the Pharma Conversations podcast, Patrick Nieuwenhuizen – Managing Director of Paradigm Pharmaceutical Quality Consultancy (PPQC) offered a rich and detailed exploration of this shift. Drawing on decades of experience in sterility assurance, quality systems, and global regulatory interactions, Patrick provided a grounded, practical, and forward-looking perspective on what unannounced inspections mean for pharmaceutical manufacturers and how organisations can adapt to this new reality.
The conversation opened with a fundamental clarification: unannounced inspections are exactly what the term implies. As Patrick stated, “as it is in the word, it’s unannounced.” Unlike traditional inspections, which typically provide four to six weeks’ notice, unannounced inspections occur without warning. This means companies have no opportunity to prepare, reorganise, or rehearse. While European regulators such as the EMA and HPRA typically used unannounced visits for “triggered inspections” or “For Cause Inspection”, the FDA’s recent decision to extend this practice to overseas facilities marks a significant shift in regulatory strategy. Patrick explained that the FDA “wanted to have a level playing field with US based companies, and not having the overseas companies the benefit to prepare themselves, as unannounced inspections are common in the US” ensuring that compliance reflects genuine day-to-day operations rather than the curated state often presented during scheduled inspections.
This shift is already being felt in Ireland. As Patrick described, “all of a sudden the FDA… appeared on the doorstep of pharmaceutical companies within Ireland,” signalling a clear escalation in regulatory expectations. The implications for manufacturers are profound. Companies must now operate under the assumption that inspectors could arrive at any moment, and their systems, behaviours, and documentation must be inspection ready every day, not just during the weeks leading up to a planned visit. This represents a fundamental change in mindset, requiring organisations to embed inspection readiness into their culture, processes, and daily routines.
Patrick emphasised that this new reality demands a shift from episodic preparation to continuous operational discipline. “You need to be inspection ready at all times, and although a company must continuously adhere to GMP, now the process of inspection readiness must also be in place” he said, highlighting that activities traditionally deferred until an inspection was announced, such as tidying documentation, preparing SMEs, or rehearsing responses, must now be embedded into routine operations. Even tasks that typically “only come up to the surface during a real inspection” must be maintained continuously. This requires a level of organisational maturity and cultural alignment that goes far beyond procedural compliance.
